Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -27235.71% is 1403% below its 5-year average of -1812.42%, near the low end of its 5-year range (-38337.50%–2979.39%).
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
-27235.71%
NET PROFIT MARGIN AVG TTM
0.00%
NET PROFIT MARGIN AVG 3Y
-1062.56%
NET PROFIT MARGIN AVG 5Y
-1812.42%
NET PROFIT MARGIN AVG 10Y
-1640.63%
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
-2463.23%
CURRENT VS 5Y AVG
-1402.73%
CURRENT VS 10Y AVG
-1560.07%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 729 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Entera Bio Ltd.
Market Cap
$126.92M
Net Profit Margin
-27235.71%
TTM Avg
0.00%
3Y Avg
-1062.56%
5Y Avg
-1812.42%
Market Cap
$124.91M
Net Profit Margin
-691.81%
TTM Avg
-1168.24%
3Y Avg
-584.12%
5Y Avg
-389.41%
Market Cap
$122.89M
Net Profit Margin
-2258.89%
TTM Avg
-4695.34%
3Y Avg
-8719.58%
5Y Avg
-5863.11%
Market Cap
$131.53M
Net Profit Margin
-90.61%
TTM Avg
-39.94%
3Y Avg
-42.38%
5Y Avg
-48.96%
Market Cap
$122.27M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$122.26M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$121.76M
Net Profit Margin
-490.71%
TTM Avg
-538.75%
3Y Avg
-569.71%
5Y Avg
-1398.02%
Market Cap
$134.21M
Net Profit Margin
27.54%
TTM Avg
-18.99%
3Y Avg
-63.93%
5Y Avg
-73.34%
Market Cap
$134.00M
Net Profit Margin
-803.83%
TTM Avg
-526.75%
3Y Avg
-263.38%
5Y Avg
-175.58%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $126.92M | -27235.71% | 0.00% | -1062.56% | -1812.42% |
| NRx Pharmaceuticals, Inc. (NRXP)vs › | $124.91M | -691.81% | -1168.24% | -584.12% | -389.41% |
| Cibus, Inc. (CBUS)vs › | $122.89M | -2258.89% | -4695.34% | -8719.58% | -5863.11% |
| Health Catalyst, Inc. (HCAT)vs › | $131.53M | -90.61% | -39.94% | -42.38% | -48.96% |
| TuHURA Biosciences, Inc. (HURA)vs › | $122.27M | 0.00% | 0.00% | 0.00% | 0.00% |
| enGene Holdings Inc. (ENGN)vs › | $122.26M | 0.00% | 0.00% | 0.00% | 0.00% |
| Seer, Inc. (SEER)vs › | $121.76M | -490.71% | -538.75% | -569.71% | -1398.02% |
| Organigram Global Inc. (OGI)vs › | $134.21M | 27.54% | -18.99% | -63.93% | -73.34% |
| Pyxis Oncology, Inc. (PYXS)vs › | $134.00M | -803.83% | -526.75% | -263.38% | -175.58% |
| LifeMD, Inc. (LFMD)vs › | $135.17M | -10.40% | -6.28% | -16.07% | -47.85% |
Operating Margin
-27450.0%
Net Profit Margin
-27235.7%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | -6111.90% |
| 2024-12-31 | -2875.61% |
| 2024-09-30 | -7192.86% |
| 2024-06-30 | -3763.16% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | -21678.57% |
| 2022-09-30 | -38337.50% |
| 2022-06-30 | -7238.64% |
| 2022-03-31 | -5564.71% |
| 2021-12-31 | 2979.39% |
| 2021-09-30 | -2304.29% |
| 2021-06-30 | -2364.22% |
| 2021-03-31 | -1462.42% |
| 2020-12-31 | -1018.55% |
| 2020-09-30 | -3248.00% |
| 2020-06-30 | -6134.62% |
| 2020-03-31 | -6947.62% |
| 2019-12-31 | -3372.55% |
| 2019-09-30 | -4990.00% |
| 2019-06-30 | -1845.95% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | -529.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | 0.00% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | 0.00% |
